EP Patent

EP1861395B1 — 5-(1,3-diaryl-1h-pyrazol-4-ylmethylene)-thiazolidine-2,4-dione derivatives useful as anticancer agent

Assigned to Korea Research Institute of Chemical Technology KRICT · Expires 2010-12-29 · 15y expired

What this patent protects

The present invention relates to a 5 - (1,3 - diaryl - 1H -pyrazol- 4 - ylmethylene ) - thiazolidine - 2,4 - dione derivative or its pharmaceutically acceptable salts thereof, a method for preparing the same and an anticancer agent composition comprising the same as an active ing…

USPTO Abstract

The present invention relates to a 5 - (1,3 - diaryl - 1H -pyrazol- 4 - ylmethylene ) - thiazolidine - 2,4 - dione derivative or its pharmaceutically acceptable salts thereof, a method for preparing the same and an anticancer agent composition comprising the same as an active ingredient .

Drugs covered by this patent

Patent Metadata

Patent number
EP1861395B1
Jurisdiction
EP
Classification
Expires
2010-12-29
Drug substance claim
No
Drug product claim
No
Assignee
Korea Research Institute of Chemical Technology KRICT
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.